Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Bauer, M; Buser, A; Dierks, C; Halimeh, S; Henschler, R; Holtick, U; Humpe, A; Kalus, U; Kron, F; Langer, F; Leitner, G; Ostermann, H; Pruss, A; Rummler, S; Scheid, C; Schennach, H; Schlenke, P; Schoensteiner, S.
Pathogen Inactivation for Ensuring a High-Quality, Safe, and Cost-effective Supply of Platelet Concentrates in Germany
GESUNDH QUAL. 2024; 29(06): 329-338.
Doi: 10.1055/a-2464-5009
Web of Science
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Schlenke Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Aim Pathogen inactivation (PI) is a globally recognized method for enhancing the safety of platelet concentrates and plasma. This publication examines the necessity and potential benefits of implementing PI for platelet concentrates in Germany. Method The analysis includes data on the current blood supply, infection risks associated with platelet concentrates, and existing safety standards, also in international comparison. Results The results show that PI improves safety by inactivating known and unknown pathogens, extends shelf life, expands the donor pool, and reduces the number of discarded platelet concentrates. This stabilizes supply and reduces costs. Conclusion The integration of PI into the German hemotherapy guideline and accelerated approval processes are recommended.
- Find related publications in this database (Keywords)
- pathogen inactivation
- blood supply
- transfusion safety
- infection risk
- hemotherapy
- pathogen inactivation
- blood supply
- transfusion safety
- infection risk
- hemotherapy